The "Stop CMV Act of 2025" aims to establish a nationwide framework for the screening of congenital Cytomegalovirus (CMV) in newborns. It permits hospitals and healthcare entities to administer CMV tests to infants 21 days old or younger, while empowering states to develop and implement their own screening standards and procedures, including recording results, tracking, and follow-up activities. If a state fails to establish approved standards within two years, the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children will prescribe them. The bill authorizes federal grants to support these efforts, with the Health Resources and Services Administration (HRSA) providing funds to states for testing, and the Centers for Disease Control and Prevention (CDC) offering grants for data collection, education, and training for healthcare providers and the public. Furthermore, the legislation directs the National Institutes of Health (NIH) to expand research into new CMV screening techniques, intervention efficacy, diagnostics, prevention strategies, and the development of treatments and vaccines. The Advisory Committee on Heritable Disorders in Newborns and Children will also be tasked with overseeing and approving these state-level CMV screening activities.